The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation
Open accessAbstract
BACKGROUND: , locking it in its inactive state. Adagrasib showed clinical activity and had an acceptable adverse-event profile in the phase 1-1b part of the KRYSTAL-1 phase 1-2 study. METHODS: -mutated non-small-cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy and anti-programmed death 1 or programmed death ligand 1 therapy. The primary end point was objective response assessed by blinded independent central review. Secondary end points included the duration of response, progression-free survival, overall survival, and safety. RESULTS: -mutated NSCLC had been treated (median follow-up, 12.9 months); 98.3% had previously received both chemotherapy and immunotherapy. Of 112 patients with measurable disease at baseline, 48 (42.9%) had a confirmed objective response. The median duration of response was 8.5 months (95% confidence interval [CI], 6.2 to 13.8), and the median progression-free survival was 6.5 months (95% CI, 4.7 to 8.4). As of January 15, 2022 (median follow-up, 15.6 months), the median overall survival was 12.6 months (95% CI, 9.2 to 19.2). Among 33 patients with previously treated, stable central nervous system metastases, the intracranial confirmed objective response rate was 33.3% (95% CI, 18.0 to 51.8). Treatment-related adverse events occurred in 97.4% of the patients - grade 1 or 2 in 52.6% and grade 3 or higher in 44.8% (including two grade 5 events) - and resulted in drug discontinuation in 6.9% of patients. CONCLUSIONS: -mutated NSCLC, adagrasib showed clinical efficacy without new safety signals. (Funded by Mirati Therapeutics; ClinicalTrials.gov number, NCT03785249.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These results indicate the rapid development of acquired resistance to KRAS G12C inhibitors [18, 26, 27, 49].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The data from both CodeBreak 100 for sotorasib and KRYSTAL-1 for adagrasib led to the approval of these inhibitors to treat G12C-mutant NSCLC [51,53,94].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [94]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In clinical trials, the inactive-state KRASG12C mutant-specific inhibitors adagrasib (MRTX849) and sotorasib (AMG510) achieved 37–43% anti-tumor response rates in NSCLC patients with most experiencing disease progression 6–12 months after initiation of therapy7–9.”
From Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer (2024) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“STK11/LKB1 loss and KEAP1 mutations may contribute to lack of response to different therapies including anti-PD-(L)1 immune checkpoint inhibitors9,10 and KRASG12C inhibitors3,4.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For adagrasib, an ORR was 23.0% in CRC, compared to 42.8% in NSCLC (Table 1) [27, 48].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [27]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Colorectal cancer, in particular, has a markedly lower response rate to KRAS G12C inhibitors compared to non-small cell lung cancer.”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, the therapeutic response to KRAS G12C inhibition was short-lived, with quick emergence of acquired resistance.”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Even in NSCLC patients, the response to KRAS G12C inhibitors was often short-lived, with a DOR of 10.9–11.1 months and PFS of 6.3–6.8 months for sotorasib, and a DOR of 8.5 months and PFS of 6.5 months for adagrasib (Table 1).”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, sotorasib, adagrasib, and divarasib monotherapies have demonstrated objective response rates ranging from 7.1% to 53.4% and median progression-free survival of 4.0-13.1 months, 13-20”
From Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer (2024) · cites this paper as [18]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The overall response rate of inactive-state KRASG12C inhibitors sotorasib and adagrasib in patients with KRASG12C mutant NSCLC is 37-43%, a major advance albeit with significant room for improvement7,8.”
From Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer (2024) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“This is further supported by a numerically higher ORR seen with divarasib in patients with non-small cell lung cancer (56.4%) compared with sotorasib (37% in a phase 2 trial and 28% in a phase 3 trial) and adagrasib (43% in a phase 2 trial)11,23–25.”
From Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial (2024) · cites this paper as [24]
The cited source says what the claim attributes to it.
In the citing paper
“Clinical studies have shown that many patients with KRAS G12C cancers did not respond to sotorasib and adagrasib.”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [27]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Because KRAS mutations are often clonal founder events, mutant KRAS ctDNA can serve as a highly informative molecular marker for tumor burden, treatment response, minimal residual disease, and emergence of resistance [29,47,77,78].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [29]
Experimental — accuracy not yet measuredIn the citing paper
“Adagrasib is a selective, irreversible inhibitor of KRASG12C and has favorable properties, including long half-life (23 hours), dose-dependent pharmacokinetics, and central nervous system penetration (3–5).”
From Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer (2024) · cites this paper as [4]
In the citing paper
“Adagrasib is a selective, irreversible inhibitor of KRASG12C and has favorable properties, including long half-life (23 hours), dose-dependent pharmacokinetics, and central nervous system penetration (3–5).”
From Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer (2024) · cites this paper as [4]
In the citing paper
“Adagrasib is a selective, irreversible inhibitor of KRASG12C and has favorable properties, including long half-life (23 hours), dose-dependent pharmacokinetics, and central nervous system penetration (3–5).”
From Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer (2024) · cites this paper as [4]
In the citing paper
“Adagrasib is a selective, irreversible inhibitor of KRASG12C and has favorable properties, including long half-life (23 hours), dose-dependent pharmacokinetics, and central nervous system penetration (3–5).”
From Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer (2024) · cites this paper as [4]
In the citing paper
“Adagrasib is a selective and irreversible oral small-molecule inhibitor of the mutant KRAS G12C protein18 and was recently approved by the FDA for treatment of NSCLC who have received at least 1 prior systemic therapy19.”
From Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients (2023) · cites this paper as [19]
In the citing paper
“This subset of patients that were evaluable for longitudinal KRASG12C ctDNA response in Cohort A exhibited a slightly higher ORR (56.4%, 22/39 cycle ctDNA response evaluable) compared to Cohort A overall (50.5%, 48/95 RECIST 1.1 evaluable patients)19”
From Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients (2023) · cites this paper as [19]
In the citing paper
“Updated data from 116 patients with previously treated NSCLC included in a registrational phase II cohort of KRYSTAL-1 showed an ORR of 42.9%, a DCR of 79.5%, median DoR of 8.5 months, median PFS of 6.5 months, median OS of 12.6 months and estimated 1-year OS of 50.8% with adagrasib83.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [83]
In the citing paper
“While these drugs clearly have clinical activity, overall response rates (30-40%) and disease control (~60%) in NSCLC are modest and transient, with median duration less than one year (9,10).”
From Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy (2023) · cites this paper as [10]
In the citing paper
“Multiple mechanisms of intrinsic and acquired resistance (10,12,13), have been identified; hence, drug combinations will likely be needed to maximize the clinical efficacy of G12Cis (and probably other, emerging KRAS inhibitors) in NSCLC and other diseases.”
From Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy (2023) · cites this paper as [10]
In the citing paper
“The phase II portion of KRYSTAL-2 included 116 patients with KRAS G12C NSCLC treated with adagrasib 600 mg bid [100]. All patients had prior platinum-doublet chemotherapy and 98.3% had received both chemotherapy and checkpoint inhibitor therapy. With a median follow-up of 12.9 months, the ORR was 42.9%.”
From Drugging KRAS: Current perspectives and state-of-art review (2022) · cites this paper as [100]
In the citing paper
“Among 33 patients with previously treated, stable central nervous system metastases, the intracranial confirmed objective response rate was 33.3% (95% CI, 18.0–51.8) [100].”
From Drugging KRAS: Current perspectives and state-of-art review (2022) · cites this paper as [100]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
Self-citationGaron, E. B., Ciuleanu, T.-E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., Park, K., Gorbunova, V., Kowalyszyn, R. D., Pikiel, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60845-x · Cited by 1,309
Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304
Self-citationAllele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691
Fell, J. B., Fischer, J. P., Baer, B. R., Blake, J. F., Bouhana, K., Briere, D. M., Brown, K. D., Burgess, L. E., Burns, A. C., Burkard, M. R., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02052 · Cited by 653
Self-citationRapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
Xue, J. Y., Zhao, Y., Aronowitz, J., Mai, T. T., Vides, A., Qeriqi, B., Kim, D., Li, C., de Stanchina, E., Mazutis, L., et al. (2020) · Nature · doi:10.1038/s41586-019-1884-x · Cited by 543
Mehta, M. P., Rodrigus, P. T. R., Terhaard, C. H. J., Rao, A. R., Suh, J. H., Roa, W., Souhami, L., Bezjak, A., Leibenhaut, M. H., Komaki, R. U., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.122 · Cited by 466
Targeting the untargetable KRAS in cancer therapy
Liu, P., Wang, Y., & Li, X. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.03.002 · Cited by 366
Flagged first, then by citations
Research works printed but not linked: 1
- Mirati Therapeutics. U.S. Food and Drug Administration (FDA) accepts Mirati Therapeutics’ new drug application for adagrasib as treatment of previously treated KRASG12C-mutated non-small cell lung cancer. February 15 2022 (https://ir.mirati.com/press-releases/press-release-details/2022/U.S.-Food-and-Drug-Administration-FDA-Accepts-Mirati-Therapeutics-New-Drug-Application-for-Adagrasib-as-Treatment-of-Previously-Treated-KRASG12C-Mutated-Non-Small-Cell-Lung-Cancer/default.aspx).
Cited by
Sorted by citations
Items 301–400 of 1,002
Loos, N. H. C., Retmana, I. A., Rijmers, J., Wang, Y., Gan, C., Lebre, M. C., Sparidans, R. W., Beijnen, J. H., & Schinkel, A. H. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115304 · Cited by 13
Small Molecules against Metastatic Tumors: Concrete Perspectives and Shattered Dreams
Serra, M., Rubes, D., Schinelli, S., & Paolillo, M. (2023) · Cancers · doi:10.3390/cancers15164173 · Cited by 13
Adagrasib in Non–Small-Cell Lung Cancer
Kotecha, R., Sahgal, A., & Mehta, M. P. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2210539 · Cited by 13
Oya, Y., & Mitsudomi, T. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-97 · Cited by 14
50 Years of Progress in NSCLC: A New Fellow’s Guide in the Clinic
Naidoo, J., Niroula, A., Uprety, D., Smeltzer, M. P., Geissen, N. M., Osarogiagbon, R. U., Mino-Kenudson, M. A., Yatabe, Y., Higgins, K. A., Desai, A. P., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.06.028 · Cited by 13
Popescu, B., Jones, M. F., Piao, M., Tran, E., Koh, A., Lomeli, I., Peretz, C. A. C., Murad, N. F., Abelson, S., Morales, C. E., et al. (2025) · Blood · doi:10.1182/blood.2025030558 · Cited by 16
Herzberg, B. O., & Manji, G. A. (2023) · The Oncologist · doi:10.1093/oncolo/oyad014 · Cited by 15
Fukuda, J., Kosuge, S., Satoh, Y., Sekiya, S., Yamamura, R., Ooshio, T., Hirata, T., Sato, R., Hatanaka, K. C., Mitsuhashi, T., et al. (2024) · Cancer Science · doi:10.1111/cas.16100 · Cited by 13
Luo, J., Florez, N., Donnelly, A., Lou, Y., Lu, K., Ma, P. C., Spira, A. I., Ryan, D. L., & Husain, H. (2024) · JCO Precision Oncology · doi:10.1200/po.23.00644 · Cited by 12
Self-citationPrecision nanomedicine to treat non-small cell lung cancer
Dessai, A. D., Nayak, U. Y., & Nayak, Y. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122614 · Cited by 13
Zhang, H., Zhang, Y., Zhu, Y., Dong, T., & Liu, Z. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1387345 · Cited by 14
Ancestry-associated co-alteration landscape of KRAS and EGFR-altered non-squamous NSCLC
Sisoudiya, S. D., Houle, A. A., Fernando, T. M., Wilson, T. R., Schutzman, J. L., Lee, J., Schrock, A. B., Sokol, E. S., Sivakumar, S., Shi, Z., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00644-4 · Cited by 13
Molecular Profiling of Low‐Grade Appendiceal Mucinous Neoplasms ( LAMN )
Doll, J., Maurus, K., Köhler, F., Matthes, N., Lock, J. F., Germer, C., Rosenwald, A., & Wiegering, A. (2024) · Genes Chromosomes and Cancer · doi:10.1002/gcc.23270 · Cited by 12
He, Q., Liu, X., Jiang, L., Liu, P., Xuan, W., Wang, Y., Meng, R., Feng, H., Lv, S., Miao, Q., et al. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2441499 · Cited by 13
Baltanás, F. C., Kramer‐Drauberg, M., García‐Navas, R., Patrucco, E., Petrini, E., Arnhof, H., Juan, A. O.-S., Rodríguez-Ramos, P., Borrajo-Sánchez, J., Calzada, N., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2422943122 · Cited by 16
Recent advances in therapeutic targeting of the KRAS pathway in cancer
Hitchen, N., Williams, S., & Desai, J. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108889 · Cited by 15
The complex journey of targeting RAS in oncology
Wasiak, K., Ciunowicz, D., Kierasińska, A., Węgierska, M., Pacholczyk, M., Rieske, P., & Stoczyńska-Fidelus, E. (2025) · BMC Cancer · doi:10.1186/s12885-025-14033-y · Cited by 14
Ciardiello, D., Chiarazzo, C., Famiglietti, V., Damato, A., Pinto, C., Zampino, M. G., Castellano, G., Gervaso, L., Zaniboni, A., Oneda, E., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100567 · Cited by 13
Molecular profiling and prognostic biomarkers in chinese non-small cell lung cancer cohort
Shen, F., Guo, W., Song, X., & Wang, B. (2023) · Diagnostic Pathology · doi:10.1186/s13000-023-01349-1 · Cited by 13
Pharmacological Profile of Novel Anti-cancer Drugs Approved by USFDA in 2022: A Review
Sangwan, K., Sharma, V., & Goyal, P. K. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230622151034 · Cited by 12
KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges
Moldvay, J., & Tı́már, J. (2024) · Pathology & Oncology Research · doi:10.3389/pore.2023.1611580 · Cited by 15
Sato, K., Akamatsu, H., Koh, Y., Ogawa, K., Isa, S., Ando, M., Tamiya, A., Kubo, A., Kitagawa, C., Kawaguchi, T., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-10246-7 · Cited by 13
Mechanisms of resistance to active state selective tri-complex RAS inhibitorsPreprint
Sang, B., Ye, L. F., Hu, F., Pourfarjam, Y., Cuevas-Navarro, A., Fan, S., Fu, Z. Q., Washington, A., Rodriguez, D. J., Vides, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.24.649345 · Cited by 12
Self-citationLKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers
Li, C., Syed, M. U., Nimbalkar, A., Shen, Y., Vieira, M. D., Fraser, C., Inde, Z., Qin, X., Ouyang, J., Kreuzer, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58753-y · Cited by 11
“For instance, STK11 /LKB1 loss and KEAP1 mutations may contribute to lack of response to different therapies including anti-PD-(L)1 immune checkpoint inhibitors 9,10 and KRAS G12C inhibitors 3,4 .”
Self-citationPrecision immune regulation in KRAS-mutated cancers: the final piece of the puzzle?
Fu, S., Ma, J., Cai, C., Tan, J., Deng, X., Shen, H., Zeng, S., Chen, Y., & Han, Y. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03444-1 · Cited by 11
Somatic mutations of thymic epithelial tumors with myasthenia gravis
Pardini, E., Cucchiara, F., Palumbo, S., Tarrini, G., Vita, A. D., Coppedè, F., Nicolì, V., Guida, M., Maestri, M., Ricciardi, R., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1224491 · Cited by 11
KRASG12C inhibition using MRTX1257: a novel radio-sensitizing partner
Laurent, P.-A., Milić, M., Quevrin, C., Meziani, L., Liu, W., Morel, D., Signolle, N., Clémenson, C., Lévy, A., Mondini, M., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04619-0 · Cited by 12
Innovative drugs promote precision cancer therapy
Huang, X., Zhu, M., Chen, R., Ni, J., Zhao, W., Li, S., Lü, X., Jiao, H., & Cao, X. (2023) · Clinical Cancer Bulletin · doi:10.1007/s44272-023-00002-8 · Cited by 12
Resistance to KRAS inhibition in advanced non-small cell lung cancer
Sreter, K. B., Catarata, M. J., von Laffert, M., & Frille, A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1357898 · Cited by 12
Advanced technologies for screening and identifying covalent inhibitors
Guo, Y., Wen, S., Tong, A., & Wang, Y. (2024) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2024.117833 · Cited by 11
Zhou, Q. H., Yang, N., Zhao, M., Huang, D., Zhao, J., Yu, Y., Yuan, Y., Sun, L., Dong, X., Zhang, T., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114337 · Cited by 11
Cina, C., Majeti, B. K., O’Brien, Z., Wang, L., Clamme, J., Adami, R. C., Tsang, K. Y., Harborth, J., Ying, W., & Zabludoff, S. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0915 · Cited by 15
Emerging Therapies for Brain Metastases in NSCLC, Breast Cancer, and Melanoma: A Critical Review
Podder, V., Ranjan, T., Gowda, M., Camacho, A. M., & Ahluwalia, M. S. (2024) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-024-01388-1 · Cited by 12
Innovative laboratory techniques shaping cancer diagnosis and treatment in developing countries
Lawal, A. O., Ogunniyi, T. J., Oludele, O. I., Olorunfemi, O. A., Okesanya, O. J., Ogaya, J. B., Manirambona, E., Ahmed, M. M., & Lucero‐Prisno, D. E. (2025) · Discover Oncology · doi:10.1007/s12672-025-01877-w · Cited by 11
Advances in the Management of Central Nervous System Metastases in Non-Small Cell Lung Cancer
D’Aiello, A., Miao, E., & Cheng, H. (2023) · Cancers · doi:10.3390/cancers15030844 · Cited by 13
Kruithof, P. D., de Beer, Y. M., Gulikers, J. L., Stolk, L. M., Hendriks, L. E. L., Croes, S., & van Geel, R. M. J. M. (2023) · Journal of Chromatography B · doi:10.1016/j.jchromb.2023.123918 · Cited by 11
Bernstein, E., Luo, J., Wang, K., Negrao, M. V., Jänne, P. A., & Sabari, J. K. (2024) · JCO Precision Oncology · doi:10.1200/po.23.00447 · Cited by 10
Self-citationLi, N., Zhang, X., Chen, J., Gao, S., Wang, L., & Zhao, Y. (2023) · Cancers · doi:10.3390/cancers15030953 · Cited by 11
Non-Small Cell Lung Cancer Testing on Reference Specimens: An Italian Multicenter Experience
Pepe, F., Russo, G., Venuta, A., Scimone, C., Nacchio, M., Pisapia, P., Goteri, G., Barbisan, F., Chiappetta, C., Pernazza, A., et al. (2024) · Oncology and Therapy · doi:10.1007/s40487-023-00252-5 · Cited by 10
Current status of molecular diagnostics for lung cancer
Имянитов, Е. Н., Преображенская, Е. В., & Орлов, С. В. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00244 · Cited by 15
Xiao, F., Wang, K., Wang, X., Li, H., Hu, Z., Ren, X., Huang, W., Feng, T., Yao, L., Lin, J., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0049 · Cited by 10
Spicer, J., Blais, N., Owen, S., Robinson, A., Chu, Q. S.-C., Labbe, C., Shieh, B., Brown-Walker, P., Sederias, J., Jensen, K., et al. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.09.003 · Cited by 10
Vitale, A., Mastrantoni, L., Russo, J., Giacomini, F., Giannarelli, D., Duranti, S., Vita, E., Nero, C., D’Argento, E., Pasciuto, T., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.24.00297 · Cited by 12
Inhibition and degradation of NRAS with a pan-NRAS monobody
Whaby, M., Ketavarapu, G., Koide, A., Mazzei, M., Mintoo, M. J., Glasser, E., Patel, U. R., Nasarre, C., Sale, M. J., McCormick, F. P., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03186-y · Cited by 11
Cilliers, C., Howgate, E. M., Jones, H. M., Rahbæk, L., & Tran, J. Q. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3506 · Cited by 10
FGTI-2734 Inhibits ERK Reactivation to Overcome Sotorasib Resistance in KRAS G12C Lung Cancer
Kazi, A., Vasiyani, H., Ghosh, D., Bandyopadhyay, D., Shah, R. D., Vudatha, V., Trevino, J., & Sebti, S. M. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.11.022 · Cited by 10
Hashimoto, A., & Hashimoto, S. (2024) · Cancers · doi:10.3390/cancers16234094 · Cited by 11
Wei, K., Sun, T., Feng, X., Yang, C., Liu, Q., & Tang, H. (2025) · BMC Cancer · doi:10.1186/s12885-025-13868-9 · Cited by 10
Wang, Z., Cai, G., Zhu, J., Wang, J., & Zhang, Y. (2025) · Molecular and Clinical Oncology · doi:10.3892/mco.2025.2837 · Cited by 12
Gales, L. N., Păun, M.-A., Butnariu, I., Simion, L., Manolescu, L. S. C., Trifanescu, O. G., & Anghel, R. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073123 · Cited by 12
Nondegradative Synthetic Molecular Glues Enter the Clinic
Repity, M. L., Deutscher, R. C. E., & Hausch, F. (2025) · ChemMedChem · doi:10.1002/cmdc.202500048 · Cited by 10
Denitrogenative Alkylation of K-Ras(G12D) Inhibits Oncogenic Signaling in Cancer Cells
Zheng, Q., & Shokat, K. M. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c06745 · Cited by 9
Solanki, H. S., Shah, H., Imbody, D. J., Desai, B., Kato, R., Miroshnychenko, D., Stern, Y. E., Majumder, A., Sarcar, B., Xieraili, A., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-0600 · Cited by 10
Oliveira, R. J. D. S., Gomes, I. N. F., da Silva, L. S., Lengert, A. V. H., Laus, A. C., Melendez, M. E., Munari, C. C., Cury, F. D. P., Longato, G. B., & Reis, R. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147774 · Cited by 10
Chmielewska, I., Krawczyk, P. A., Grenda, A., Wójcik-Superczyńska, M., Krzyżanowska, N., Gil, M., & Milanowski, J. (2023) · Cancers · doi:10.3390/cancers15143732 · Cited by 10
Gao, L., & Shen, W. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.890247 · Cited by 11
Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinomaPreprint
Wasko, U. N., Jiang, J., Curiel‐García, Á., Wang, Y., Lee, B. J., Orlen, M., Drizyte‐Miller, K., Menard, M. J., Dilly, J., Sastra, S. A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.03.569791 · Cited by 10
Wang, P., Sun, X., He, X., Kang, D., Liu, X., Liu, D., Li, A., Yang, G., Lin, Y., Li, S., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0001 · Cited by 9
Updates in Drug-Related Pneumonitis Due to Targeted Oncologic Therapies
Chan, K. L., Faiz, S. A., Altan, M., & Sheshadri, A. (2024) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-24-12 · Cited by 9
Emerging Tumor-Agnostic Molecular Targets
Bhamidipati, D., & Schram, A. M. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0725 · Cited by 9
Preclinical evaluation of targeted therapies for central nervous system metastases
Pfeil, A. J., Hale, J., Zhang, T., Wakayama, K., Miyazaki, I., Odintsov, I., & Somwar, R. (2024) · Disease Models & Mechanisms · doi:10.1242/dmm.050836 · Cited by 10
Peng, T., Wu, T., Yi, T.-Y., & Wu, A. (2024) · Cancers · doi:10.3390/cancers16213676 · Cited by 9
Ramalingam, P. S., Raj, D. B. T. G., Subramanian, M., & Arumugam, S. (2024) · Advances in Public Health · doi:10.1155/2024/9436238 · Cited by 9
Advances in the Treatment of Rare Mutations in Non-Small Cell Lung Cancer
Sun, Y., Ma, L., Zhang, X., & Wang, Z. (2024) · OncoTargets and Therapy · doi:10.2147/ott.s487870 · Cited by 10
Hernandez‐Martinez, J., Güijosa, A., Flores‐Estrada, D., Cruz‐Rico, G., Turcott, J. G., Hernández‐Pedro, N., Caballé‐Perez, E., Cardona, A. F., & Arrieta, O. G. (2024) · JCO Global Oncology · doi:10.1200/go-24-00338 · Cited by 14
Pandey, A. K., Rohweder, P. J., Chan, L. M., Ongpipattanakul, C., Chung, D. H., Paolella, B., Quimby, F. M., Nguỹên, N. B., Verba, K. A., Evans, M. J., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-2450 · Cited by 11
Evolution of first versus next-line targeted therapies for metastatic non-small cell lung cancer
Waliany, S., Lin, J. J., & Gainor, J. F. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.01.005 · Cited by 10
Immune-Based Strategies for Pancreatic Cancer in the Adjuvant Setting
Liang, K.-L., & Azad, N. S. (2025) · Cancers · doi:10.3390/cancers17071246 · Cited by 9
IGF-1R Inhibitors in Cancer: A Review of Available Evidence and Future Outlook
Guven, D., Ahmed, J., Stephen, B., & Naing, A. (2025) · Critical reviews in oncology/hematology · doi:10.1016/j.critrevonc.2025.104809 · Cited by 10
KRAS/ABHD17C/ALOX15B Axis Promotes Pancreatic Cancer Progression via Ferroptosis Evasion
Li, M., Yu, X., Liu, Y., Ouyang, S., Wu, L., Chen, X., Yu, H. J., Chen, H., Lian, S., Li, Z., et al. (2025) · Advanced Science · doi:10.1002/advs.202504470 · Cited by 9
Inverted chimeric RNAi molecules synergistically cotarget MYC and KRAS in KRAS-driven cancers
Chareddy, Y. S., Huggins, H. P., Sahoo, S. S., Stanland, L. J., Gutierrez-Ford, C., Whately, K. M., Edatt, L., Azam, S. H., Fleming, M. C., Im, J., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci187204 · Cited by 11
Hartner, S., Abolfathi, H., Rezanejad, M., Liu, B., Karimi, E., Rogers, D., Sorin, M., Doré, S., Desharnais, L., Orain, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63465-4 · Cited by 10
Kumar, V., Meenu, Shaquiquzzaman, M., Alam, M. A., Akhter, M., Parveen, D., Kaleem, M., Charan, S., Saifullah, M. K., & Tasneem, S. (2026) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2026.110527 · Cited by 12
Stahlhut, C. E., Maciag, A. E., Sullivan, K. A., Singh, K., Gitego, N., Zhang, Z., Chan, A. H., Sharma, A. K., Alexander, P., Shu, J., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-1280 · Cited by 10
Gregorc, V., Majem, M., Russo, G. L., Maio, M., Salvagni, S., Calderón, V. G., Gonzalez-Cao, M., Contreras, S. S., Koumarianou, A. A., Bearz, A., et al. (2026) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00764-8 · Cited by 9
AZD4625 is a Potent and Selective Inhibitor of KRASG12C
Chakraborty, A., Hanson, L. L., Robinson, D. M., Lewis, H. J., Bickerton, S., Davies, M., Polański, R., Whiteley, R., Koers, A., Atkinson, J. M., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0241 · Cited by 9
Fancelli, S., Caliman, E., Mazzoni, F., Paglialunga, L., Michelet, M. R. G., Lavacchi, D., Berardi, R., Mentrasti, G., Metro, G., Birocchi, I., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.968064 · Cited by 9
The end of the beginning: progress and next steps in KRAS-mutant non-small-cell lung cancer
Goldberg, S. B., & Herbst, R. S. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00288-x · Cited by 9
Noordhof, A. L., Swart, E. M., Damhuis, R. A. M., Hendriks, L. E. L., Kunst, P. W. A., Aarts, M. J., & van Geffen, W. H. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2023.100543 · Cited by 10
Bhamidipati, D., & Subbiah, V. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101591 · Cited by 10
Luo, W. P., Zhu, J., Zhang, W., Yu, A., Zhou, W., & Xu, K. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2282606 · Cited by 10
Tan, Y. Q., Sun, B., Zhang, X., Zhang, S., Guo, H., Basappa, B., Zhu, T., Sethi, G., Lobie, P. E., & Pandey, V. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06551-7 · Cited by 10
Zhou, Y., Zeng, Z., Li, Z., Ruan, L., Xie, H., Ye, F., Huang, L., Liu, H., & Kang, L. (2024) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848241249387 · Cited by 9
Adagrasib: a novel inhibitor for KRAS G12C -mutated non-small-cell lung cancer
Guo, M. Z., Marrone, K. A., Spira, A. I., & Rosner, S. (2023) · Future Oncology · doi:10.2217/fon-2022-1106 · Cited by 10
Self-citationKRAS takes the road to destruction
Cox, A. D., & Der, C. J. (2024) · Science · doi:10.1126/science.ads2150 · Cited by 9
Kim, M., Shim, H. S., Kim, S., Lee, I. H., Kim, J., Yoon, S., Kim, H., Park, I., Jeong, J. H., Yoo, C., et al. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2023.1043 · Cited by 8
Reyes, A. R., Afkhami, M., Massarelli, E., Fricke, J., Mambetsariev, I., Li, X., Velasquez, G., & Salgia, R. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.07.010 · Cited by 8
Sampat, P. J., Cortese, A., Goodman, A., Ghelani, G. H., Mix, M. D., Graziano, S. L., & Basnet, A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1411432 · Cited by 9
The Impact of Genetic Mutations on the Efficacy of Immunotherapies in Lung Cancer
Lui, K., Cheung, K., Ng, W. W. M., Wang, Y., Au, D. W. H., & Cho, W. C. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252211954 · Cited by 9
Li, Z., Zhou, Z., Zhang, N., Tian, B., Chen, X., Zhao, H., & Wang, H. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03858-4 · Cited by 13
Zha, Z., Liu, C., Yan, M., Chen, C., Cheng, Y., Chen, Y., Zhou, C., Li, L., Li, Y., Yamaguchi, H., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02206-x · Cited by 9
Stella, G. M., Bertuccio, F. R., Novy, C., Bortolotto, C., Salzillo, I., Perrotta, F., D’Agnano, V., Conio, V., Arici, V., Cerveri, P., et al. (2025) · Cells · doi:10.3390/cells14161225 · Cited by 7
Baird, L., Zhang, L., Hidaka, T., Xi, L., Wang, K., Tateno, K., Iso, T., Suzuki, T., Kumada, K., Katsuoka, F., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03162-7 · Cited by 10
Hibshman, P. S., Stalnecker, C. A., Klomp, J. A., Drizyte‐Miller, K., Klomp, J. E., Edwards, A. C., Pita, L. M., Hodge, R. G., Diehl, J. N., Mouery, R. D., et al. (2025) · Science Signaling · doi:10.1126/scisignal.adu7145 · Cited by 9
Bian, Y., Shan, G., Bi, G., Xu, Z., Liang, J., Yan, Y., Guo, W., Sui, Q., Yi, Y., Shi, H., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65441-4 · Cited by 11
KRAS-targeted therapies in cancer: novel approaches and overcoming resistance
Tang, D., Kroemer, G., & Kang, R. (2025) · BMJ Oncology · doi:10.1136/bmjonc-2025-000946 · Cited by 12
Bhattacharya, D., Roman, B., & Reddy, S. (2026) · Cancer Gene Therapy · doi:10.1038/s41417-026-01003-0 · Cited by 9
CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code
Brazel, D., Kim, J., & Ou, S. I. (2023) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s403614 · Cited by 8
Self-citationPan, Y., Liu, X., Zhang, W., Wang, W., Wang, H., Luo, L., Jia, K., Shao, C., Mao, S., Qiu, T., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107233 · Cited by 8
Gray, J. E., Hsu, H., Younan, D., Suri, G., Chia, V., Spira, A. I., & Johnson, M. L. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107260 · Cited by 8
Self-citation
Metadata
- Authors
- Jänne, P. A., Riely, G. J., Gadgeel, S. M., Heist, R. S., Ou, S.-H. I., Pacheco, J. M., Johnson, M. L., Sabari, J. K., Leventakos, K., Yau, E., Bazhenova, L., Negrao, M. V., Pennell, N. A., Zhang, J., Anderes, K., Der-Torossian, H., Kheoh, T., Velastegui, K., Yan, X., Christensen, J. G., Chao, R. C., & Spira, A. I.
- Affiliations
- From the Lowe Center for Thoracic Oncology, Dana–Farber Cancer Institute (P.A.J.), and Massachusetts General Hospital (R.S.H.) — both in Boston; the Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College (G.J.R.), and Perlmutter Cancer Center, New York University Langone Health (J.K.S.), New York, and the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (E.Y.) — all in New York; the Henry Ford Cancer Institute, Detroit (S.M.G.); the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.), the University of California San Diego Moores Cancer Center, La Jolla (L.B.), and Mirati Therapeutics, San Diego (K.A., H.D.-T., T.K., K.V., X.Y., J.G.C., R.C.C.) — all in California; the Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora (J.M.P.); Sarah Cannon Research Institute at...
- Roswell Park Comprehensive Cancer Center (US)
- ORCID
- Riely, Gregory J.
- Gadgeel, Shirish M.
- Heist, Rebecca S.
- Ou, Sai-Hong I.
- Johnson, Melissa L.
- Sabari, Joshua K.
- Leventakos, Konstantinos
- Yau, Edwin
- Bazhenova, Lyudmila
- Negrao, Marcelo V.
- Pennell, Nathan A.
- Zhang, Jun
- Anderes, Kenna
- Kheoh, Thian
- Velastegui, Karen
- Christensen, James G.
- Chao, Richard C.
- Spira, Alexander I.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-14
- Volume
- 387
- Issue
- 2
- Pages
- 120-131
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281650778
- Cited by
- 1,061
- References
- 27
- Citations by year
- 2026: 247 · 2025: 270 · 2024: 285 · 2023: 203 · 2022: 56
- FWCI
- 131.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Mirati Therapeutics, Inc.
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- adagrasib, KRAS G12C mutation, non-small cell lung cancer, KRAS inhibitors, objective response rate, progression-free survival, overall survival, central nervous system metastasis, treatment-related adverse events, previously treated patients
- MeSH terms
- Acetonitriles, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Piperazines, Pyrimidines, Proto-Oncogene Proteins p21(ras)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
